Antabio SAS, 31670 Labège, France.
Acc Chem Res. 2021 May 4;54(9):2055-2064. doi: 10.1021/acs.accounts.0c00863. Epub 2021 Mar 31.
Ever since the first β-lactam antibiotic, penicillin, was introduced into the clinic over 70 years ago, resistance has been observed because of the presence of β-lactamase enzymes, which hydrolyze the β-lactam ring of β-lactam antibiotics. Early β-lactamase enzymes were all of the serine β-lactamase (SBL) type, but more recently, highly resistant Gram-negative strains have emerged in which metallo-β-lactamase (MBL) enzymes are responsible for resistance. The two types of β-lactamase enzymes are structurally and mechanistically different but serve the same purpose in bacteria. The SBLs use an active serine group as a nucleophile to attack the β-lactamase ring, forming a covalent intermediate that is subsequently hydrolyzed. In contrast, the MBLs use a zinc ion to activate the β-lactam toward nucleophilic attack by a hydroxide anion held between two zinc ions. In this Account, we review our recent contribution to the field of β-lactamase inhibitor design in terms of both SBL and MBL inhibitors. We describe how we have approached these challenges from the particular perspective of a small biotechnology company, identifying new inhibitors when faced with either a paucity of starting points for medicinal chemistry (MBL inhibitors) or else an abundance of prior research necessitating a search for novelty, improvement, and differentiation (SBL inhibitors). During the journey from the beginning of lead optimization to successful identification of a preclinical candidate for development, we encountered and solved a range of issues. For example, in the MBL inhibitor series we were able to prevent metabolic cleavage of a glycinamide moiety by circulating amidases while still retaining the activity by converting the amino group into a guanidine. In the SBL inhibitor series, the structure-activity relationship led us to consider introducing a fluorine substituent adjacent to a urea functionality. At first sight this grouping would appear to be chemically unstable. However, deeper theoretical considerations suggested that this would not be the case, and in practice the compound is remarkably stable. Both examples serve to illustrate the importance of scientific insight and the necessity to explore speculative hypotheses as part of the creative medicinal chemistry process.
自 70 多年前第一种β-内酰胺抗生素青霉素引入临床以来,由于存在β-内酰胺酶,β-内酰胺抗生素的β-内酰胺环被水解,因此观察到了耐药性。早期的β-内酰胺酶都是丝氨酸β-内酰胺酶(SBL),但最近,具有高度耐药性的革兰氏阴性菌株出现了,其中金属β-内酰胺酶(MBL)负责耐药。这两种类型的β-内酰胺酶在结构和机制上有所不同,但在细菌中发挥着相同的作用。SBL 用一个活跃的丝氨酸基团作为亲核试剂攻击β-内酰胺环,形成一个随后被水解的共价中间体。相比之下,MBL 用一个锌离子激活β-内酰胺,使其受到两个锌离子之间结合的氢氧根阴离子的亲核攻击。在本报告中,我们根据 SBL 和 MBL 抑制剂,综述了我们最近在β-内酰胺酶抑制剂设计领域的贡献。我们描述了如何从一家小型生物技术公司的特定角度来应对这些挑战,确定新的抑制剂,无论是在药物化学的起始点很少(MBL 抑制剂),还是在需要寻找新颖性、改进和差异化的情况下(SBL 抑制剂)。在从先导化合物优化到成功鉴定出一个临床前候选药物的开发过程中,我们遇到并解决了一系列问题。例如,在 MBL 抑制剂系列中,我们能够阻止循环酰胺酶对甘氨酰胺部分的代谢裂解,同时通过将氨基转化为胍来保持其活性。在 SBL 抑制剂系列中,构效关系使我们考虑在脲官能团的相邻位置引入一个氟取代基。乍一看,这个基团似乎在化学上不稳定。然而,更深入的理论考虑表明事实并非如此,实际上该化合物非常稳定。这两个例子都说明了科学洞察力的重要性,以及在创造性的药物化学过程中探索推测性假设的必要性。